Large randomized controlled trials on the SGLT2 inhibitors, empagliflozin (EMPA-REG OUTCOME), canagliflozin (CANVAS PROGRAM), and dapagliflozin (DECLARE-TIMI 58) have been found to markedly reduce cardiovascular events and heart failure hospitalizations and to significantly improve renal outcomes in patients with type 2 diabetes (T2D) with a high or very high cardiovascular risk [1–3]. Here, SLC5A2 is linked to heart failure.